Italia markets close in 4 hours 59 minutes

Valneva SE (VLA.PA)

Paris - Paris Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
6,47-0,06 (-0,92%)
Al 12:06PM CET. Mercato aperto.

Valneva SE

6 rue Alain Bombard
Saint-Herblain 44800
France
33 2 28 07 37 10
https://valneva.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno762

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Thomas LingelbachChairman of the Management Board, Pres & CEO769,14kN/D1963
Mr. Franck Grimaud MBADirector Gen., Chief Bus. Officer & Member of Management Board482,35kN/D1967
Mr. Frederic JacototVP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board378,59kN/D1965
Dr. Juan-Carlos Jaramillo M.D.Chief Medical Officer & Member of the Management Board527,17kN/D1971
Mr. Peter BuhlerCFO & Management Board MemberN/DN/D1971
Mr. Perry CelentanoInterim Chief Operating OfficerN/DN/DN/D
Ms. Dipal PatelChief Commercial Officer & Member of Management BoardN/DN/DN/D
Mr. Joshua Drumm Ph.D.VP of Investor RelationsN/DN/DN/D
Ms. Laetitia Bachelot-FontaineVP of Global Communications & European Investor RelationsN/DN/DN/D
Mr. Gerald StrohmaierVP of Human ResourceN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Governance aziendale

L'ISS Governance QualityScore di Valneva SE al 1 novembre 2022 è 10. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 8; diritti degli azionisti: 5; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.